Augtyro — repotrectinib
Named-patient access overview. Augtyro is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Augtyro
Augtyro (repotrectinib) is manufactured by BMS and indicated for ROS1+ NSCLC; NTRK+ solid tumors. It is a ROS1/NTRK TKI approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Augtyro
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Augtyro for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Augtyro is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Augtyro in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Augtyro in BangladeshNamed-patient access, timeline, and regulatory notes
Augtyro in EgyptNamed-patient access, timeline, and regulatory notes
Augtyro in KuwaitNamed-patient access, timeline, and regulatory notes
Augtyro in PakistanNamed-patient access, timeline, and regulatory notes
Augtyro in QatarNamed-patient access, timeline, and regulatory notes
Augtyro in Saudi ArabiaNamed-patient access, timeline, and regulatory notes
Augtyro in Sri LankaNamed-patient access, timeline, and regulatory notes
Augtyro in United Arab EmiratesNamed-patient access, timeline, and regulatory notes
Start a request for Augtyro
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.